Company intelligence
New Street Investor Relations
A life sciences-only investor relations consulting firm.
About New Street Investor Relations
New Street Investor Relations helps biotechnology and life sciences companies navigate Wall Street, raise capital, and communicate more effectively with investors. Our team brings decades of experience across investment banking, investor relations, communications agencies, and in-house leadership roles at public and private companies. That mix of perspectives allows us to provide practical, tailored guidance across financing strategy, investor communications, market positioning, and the day-to-day demands of operating in the public markets. Founder and CEO Laurence Watts created New Street to offer companies a more personal, straightforward alternative to traditional advisory firms. We take a high-touch, collaborative approach and focus on helping each client make informed decision and build long-term value.
Verified activity
Signals from New Street Investor Relations
4 published signals
Research & Knowledge
New Street Investor Relations published the Biotech IPO League Table for August 2026, highlighting investment banks leading their offerings and the 2026 rankings shaping up.
Reported by New Street Investor Relations
Presence & Recognition
New Street Investor Relations announced that Braveheart Bio will participate in the Cantor Global Healthcare Conference being held September 9-11 in New York, NY, with Management participating in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.
Reported by New Street Investor Relations
Presence & Recognition
New Street Investor Relations announced that management plans to participate in the Cantor Global Healthcare Conference in New York City on Wednesday, September 9, 2026, and the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 23, 2026, in virtual format.
Reported by New Street Investor Relations
Presence & Recognition
New Street Investor Relations announced participation in two upcoming investor conferences, Affibody AB attending the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Tuesday, September 15, and the 4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit in New York City on Thursday, September 17.
Reported by New Street Investor Relations